Kabra Drugs

Why is Kabra Drugs Ltd falling/rising?

As of 01-Sep, Kabra Drugs Ltd's stock is declining, with a 0.86% drop and a significant 18.23% decrease over the past month. Despite strong financial results, investor interest is waning, and the stock remains below its moving averages, indicating a bearish trend.

As of 01-Sep, Kabra Drugs Ltd's stock price is currently falling, with a change of -0.17, representing a decrease of 0.86%. This decline is part of a broader trend, as the stock has experienced a significant drop of 18.23% over the past month and 35.68% year-to-date. Although the stock has outperformed its sector by 0.75% today and has shown a trend reversal after six consecutive days of decline, it is still trading below all its moving averages, indicating a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume falling by 31.07% compared to the five-day average, suggesting reduced interest in the stock. Despite the company reporting strong financial results, including a 100% growth in net profit and positive results for the last four consecutive quarters, the long-term fundamental strength appears weak. The average Return on Equity (ROE) is at 0%, and the company has a high Debt to EBITDA ratio of -0.27 times, indicating challenges in servicing debt. These factors contribute to the stock's current downward movement.

Who are in the management team of Kabra Drugs?

The management team of Kabra Drugs includes B V Anatha Kumar (Whole Time Director & CFO), R Muralidharan, Ananthkumar Shilpa, Churchil Durai M Jebastine (all Independent Directors), Nidhi Bhaskar and Monika Sanwal (Company Secretaries), KUNIAMUTHUR NANJAPPAN ANAND, and A Anitha (Additional Directors).

The management team of Kabra Drugs includes the following individuals:<BR><BR>1. B V Anatha Kumar - Whole Time Director & CFO<BR>2. R Muralidharan - Independent Director<BR>3. Ananthkumar Shilpa - Independent Director<BR>4. Churchil Durai M Jebastine - Independent Director<BR>5. Nidhi Bhaskar - Company Secretary<BR>6. KUNIAMUTHUR NANJAPPAN ANAND - Additional Director<BR>7. Monika Sanwal - Company Secretary & Compliance Officer<BR>8. A Anitha - Additional Director<BR><BR>If you have any more questions about the company or its management, feel free to ask!

What does Kabra Drugs do?

Kabra Drugs Ltd is a micro-cap pharmaceutical company based in Madhya Pradesh, specializing in Ether derivatives, with net sales of 46 Cr and a net profit of 2 Cr as of June 2026. The company was incorporated in 1989 and is the sole manufacturer of Ether derivatives in its region.

Overview:<BR>Kabra Drugs Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of Ether derivatives.<BR><BR>History:<BR>Kabra Drugs Limited was incorporated as a Limited Company on August 22, 1989. The company commenced commercial production in 1991 and is the only manufacturer of Ether derivatives in the State of Madhya Pradesh. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 46 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap: INR 49 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 6.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.43<BR>- Return on Equity: 19.08%<BR>- Price to Book: 1.82<BR><BR>Contact Details:<BR>Address: 270 Shastri Market Indore, Indore Madhya Pradesh: 452007<BR>Email: kabradrugs@rediffmail.com<BR>Website: http://www.kabradrugslimited.com

Who are the peers of the Kabra Drugs?

Kabra Drugs' peers include Shelter Pharma, Biofil Chemicals, Vasundhara Rasy., Mangalam Drugs, Parmax Pharma, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and Murae Organisor. Kabra Drugs has Below Average management risk and a 1-year return of 7.02%, while Parmax Pharma leads with a 273.20% return.

Peers: The peers of Kabra Drugs are Shelter Pharma, Biofil Chemicals, Vasundhara Rasy., Mangalam Drugs, Parmax Pharma, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and Murae Organisor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Biofil Chemicals, Vasundhara Rasy., and Rajnish Wellness. Below Average management risk is present at Mangalam Drugs, Parmax Pharma, Kabra Drugs, Vivo Bio Tech, Roopa Industries, and Murae Organisor. Growth is Excellent at Kabra Drugs and Roopa Industries, Good at Shelter Pharma and Murae Organisor, while Below Average growth is noted at Biofil Chemicals, Vasundhara Rasy., Mangalam Drugs, Parmax Pharma, Rajnish Wellness, and Vivo Bio Tech. Excellent capital structure is seen at Shelter Pharma, Good at Biofil Chemicals and Vasundhara Rasy., and Below Average at Mangalam Drugs, Parmax Pharma, Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and Murae Organisor.<BR><BR>Return Snapshot: Parmax Pharma has the highest 1-year return at 273.20%, while Rajnish Wellness has the lowest at -61.17%. Kabra Drugs' 1-year return is 7.02%, which is significantly higher than Rajnish Wellness but lower than Parmax Pharma. Additionally, the six-month return is negative for Shelter Pharma, Biofil Chemicals, Mangalam Drugs, Rajnish Wellness, Vivo Bio Tech, and Murae Organisor.

How big is Kabra Drugs?

As of 31st August, Kabra Drugs Ltd has a market capitalization of 49.00 Cr, with recent net sales of 131.81 Cr and a net profit of 7.59 Cr. The balance sheet for March 2025 shows shareholder's funds of 24.65 Cr and total assets of 25.23 Cr.

As of 31st August, Kabra Drugs Ltd has a market capitalization of 49.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kabra Drugs reported Net Sales of 131.81 Cr and a Net Profit of 7.59 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 24.65 Cr and Total Assets of 25.23 Cr.

Which are the latest news on Kabra Drugs?

Should I buy, sell or hold Kabra Drugs Ltd?

When is the next results date for Kabra Drugs Ltd?

Kabra Drugs Ltd will announce its results on 12 August 2026.

Kabra Drugs Ltd will declare its results on 12 August 2026.

How has been the historical performance of Kabra Drugs?

Kabra Drugs has consistently generated no significant revenue from March 2021 to March 2025, with increasing operating losses reaching -1.08 Cr by March 2025, despite an improvement in shareholder's funds to 24.65 Cr due to increased equity capital. Total liabilities rose to 25.23 Cr, while financing activities resulted in a net cash inflow of 18.00 Cr.

Answer:<BR>The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total liabilities rose significantly to 25.23 Cr in March 2025, while total assets also increased to the same amount, indicating a growing but unprofitable operation. Cash flow from operating activities has been negative, with a notable cash inflow from financing activities in March 2025, resulting in a net cash inflow of 18.00 Cr.<BR><BR>Breakdown:<BR>Kabra Drugs has not generated any significant revenue over the years, with net sales consistently at zero from March 2021 to March 2025, except for a slight revenue in March 2019. The total operating income has remained low, with only minor other operating income recorded in earlier years. Total expenditures have escalated, particularly in employee costs and other expenses, leading to increasing operating losses, which reached -1.08 Cr by March 2025. The company's financial position has seen a notable improvement in shareholder's funds, which rose to 24.65 Cr in March 2025, driven by a substantial increase in equity capital. However, total liabilities also surged to 25.23 Cr, reflecting the company's growing financial obligations. Despite these challenges, cash flow from financing activities provided a significant boost, resulting in a net cash inflow of 18.00 Cr in March 2025, although cash flow from operating activities remained negative.

Are Kabra Drugs latest results good or bad?

Kabra Drugs' latest results show flat net sales but a significant 228.21% decline in standalone net profit, prompting MarketsMOJO to issue a 'Sell' recommendation. Investors should be cautious due to concerns about the company's profitability in a competitive market.

Kabra Drugs' latest results for the quarter ending June 2025 indicate a flat financial performance, with no significant changes in net sales compared to the previous quarter. However, the company has experienced a notable decline in standalone net profit, which dropped by 228.21% from the previous quarter, reflecting a challenging situation. <BR><BR>Given this performance, MarketsMOJO has issued a 'Sell' call on the stock, suggesting that investors should approach with caution. Overall, while the company shows stability in some metrics, the significant drop in profitability raises concerns about its current trajectory in the competitive pharmaceuticals and biotechnology sector. Investors will likely be looking for further developments in the upcoming quarters to better assess the company's future prospects.

Who are the top shareholders of the Kabra Drugs?

The top shareholders of Kabra Drugs are primarily individual investors, holding 96.19% of the shares, with Kuniamuthur Nanjappan Anand being the largest public shareholder at 6.53%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Kabra Drugs primarily consist of individual investors, who hold a significant 96.19% of the company's shares. Among public shareholders, Kuniamuthur Nanjappan Anand stands out with a holding of 6.53%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings. Overall, the majority of the ownership is concentrated in the hands of individual investors.

Is Kabra Drugs overvalued or undervalued?

As of November 12, 2024, Kabra Drugs is rated as risky and overvalued, with negative financial ratios compared to competitors like Sun Pharma and Cipla, despite a recent short-term stock performance that outpaced the Sensex.

As of 12 November 2024, the valuation grade for Kabra Drugs has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company is currently assessed as overvalued, with a PE ratio of -27.57, an EV to EBITDA ratio of -28.95, and a ROCE of -33.00%. These negative ratios suggest that the company is facing substantial financial challenges compared to its peers.<BR><BR>In comparison to notable competitors, Kabra Drugs' valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla boasts a PE of 22.99, both indicating a much healthier valuation environment in the industry. The stark contrast in these ratios highlights the overvaluation of Kabra Drugs. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, returning 4.99% compared to the Sensex's 1.45%, but this short-term gain does not mitigate the overall valuation concerns reflected in its financial ratios.

What is the technical trend for Kabra Drugs?

As of May 27, 2025, Kabra Drugs shows a mildly bullish trend, supported by positive MACD and RSI indicators, although caution is advised due to a mildly bearish KST on the weekly chart.

As of 27 May 2025, the technical trend for Kabra Drugs has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend on the weekly chart while remaining bullish on the monthly chart. Dow Theory indicates no trend on the weekly but is mildly bullish on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the strong performance in MACD and RSI across multiple time frames.